=> d his

```
(FILE 'USPAT' ENTERED AT 17:01:48 ON 24 MAY 1999)
              5 S GP19
L1
           4176 S ADENOVIRUS
L2
              4 S L1 AND L2
L3
             39 S CTLA4
L4
             28 S CTLA4(P)ANTIBOD?
L5
            283 S COMPOSITION (6A) (IMMUNOSUPPRESS? OR IMMUNOPROTECT?)
L6
              1 S L6 AND L5
L7
              0 S L3 AND L6
\Gamma8
           9791 S METHOD (5A) EXPRESS?
L9
              3 S L9 AND L3
L10
=> s 11 or 14
           44 L1 OR L4
L11
=> s 514/44/ccls and 111
           690 514/44/CCLS
             5 514/44/CCLS AND L11
L12
=> s 514/1/ccls and 111
            83 514/1/CCLS
             0 514/1/CCLS AND L11
L13
=> s 424/130.1/ccls and 111
           309 424/130.1/CCLS
             7 424/130.1/CCLS AND L11
L14
=> s 435/320.1/ccls and 111
          5871 435/320.1/CCLS
           18 435/320.1/CCLS AND L11
L15
=> d his
      (FILE 'USPAT' ENTERED AT 17:01:48 ON 24 MAY 1999)
               5 S GP19
L1
            4176 S ADENOVIRUS
L2
              4 S L1 AND L2
L3
              39 S CTLA4
              28 S CTLA4(P)ANTIBOD?
L5
             283 S COMPOSITION (6A) (IMMUNOSUPPRESS? OR IMMUNOPROTECT?)
               1 S L6 AND L5
L7
               0 S L3 AND L6
L8
            9791 S METHOD (5A) EXPRESS?
L9
              3 S L9 AND L3
L10
              44 S L1 OR L4
L11
               5 S 514/44/CCLS AND L11
L12
              0 S 514/1/CCLS AND L11
L13
              7 S 424/130.1/CCLS AND L11
L14
             18 S 435/320.1/CCLS AND L11
L15
```

- 1. 5,882,877, Mar. 16, 1999, Adenoviral vectors for gene therapy containing deletions in the adenoviral genome; Richard J. Gregory, et al., 435/320.1, 456, 457 [IMAGE AVAILABLE]
- 2. 5,820,868, Oct. 13, 1998, Recombinant protein production in bovine adenovirus expression vector system; Suresh K. Mittal, et al., 424/199.1, 233.1; 435/235.1, 320.1 [IMAGE AVAILABLE]
- 3. 5,670,488, Sep. 23, 1997, **Adenovirus** vector for gene therapy; Richard J. Gregory, et al., 514/44; 424/93.2; 435/320.1 [IMAGE AVAILABLE]
- 4. 5,639,661, Jun. 17, 1997, Genes and proteins for treating cystic fibrosis; Michael J. Welsh, et al., 435/252.3, 320.1; 536/23.5, 24.3 [IMAGE AVAILABLE]

=> s 17

L16

1 L6 AND L5

=> s 1-3 110

MISSING OPERATOR '1-3 L10'

=> d 17

1. 5,747,034, May 5, 1998, Methods and materials for the induction of T cell anergy; Mark de Boer, et al., 424/137.1, 141.1, 156.1; 435/70.21, 329, 343.1, 343.2; 530/387.1, 387.3, 387.5, 388.1, 388.85, 809 [IMAGE AVAILABLE]

=> d 1-3 110

- 1. 5,882,877, Mar. 16, 1999, Adenoviral vectors for gene therapy containing deletions in the adenoviral genome; Richard J. Gregory, et al., 435/320.1, 456, 457 [IMAGE AVAILABLE]
- 2. 5,670,488, Sep. 23, 1997, **Adenovirus** vector for gene therapy; Richard J. Gregory, et al., 514/44; 424/93.2; 435/320.1 [IMAGE AVAILABLE]
- 3. 5,639,661, Jun. 17, 1997, Genes and proteins for treating cystic fibrosis; Michael J. Welsh, et al., 435/252.3, 320.1; 536/23.5, 24.3 [IMAGE AVAILABLE]

=> d 1-5 112

,

- 1. 5,872,154, Feb. 16, 1999, Method of reducing an immune response to a recombinant adenovirus; James M. Wilson, et al., 424/85.2, 85.5, 93.2, 93.6, 154.1, 233.1; 435/69.1, 320.1; **514/44**, 49, 50 [IMAGE AVAILABLE]
- 2. 5,869,230, Feb. 9, 1999, Gene transfer into the kidney; Vikas P. Sukhatme, 435/1.1; 424/93.2; 435/320.1, 456; **514/44**; 536/23.1 [IMAGE AVAILABLE]
- 3. 5,807,734, Sep. 15, 1998, Monoclonal antibodies and FV specific for CD2 antigen; Michael L. Diegel, et al., 435/252.33; 424/134.1, 135.1, 192.1; 435/70.21, 320.1; **514/44**; 530/387.3, 388.22; 536/23.53 [IMAGE AVAILABLE]

- 4. 5,670,488, Sep. 23, 1997, Adenovirus vector for gene therapy; Richard J. Gregory, et al., 51 4; 424/93.2; 435/320.1 [IMAGE ANAILABLE]
- 5. 5,652,224, Jul. 29, 1997, Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism; James M. Wilson, et al., 514/44; 424/93.21; 435/320.1, 325, 354, 366, 369, 370, 456 [IMAGE AVAILABLE]

=> d 1-7 114

- 1. 5,902,585, May 11, 1999, Methods of inducing T cell unresponsiveness to donor tissue or organ in a recipient with GP39 antagonists; Randolph J. Noelle, et al., 424/144.1, 130.1, 133.1, 134.1, 141.1, 143.1, 154.1, 173.1; 514/2, 8, 885; 530/350, 387.1, 387.3, 388.1, 388.2, 388.22, 388.7, 388.73, 388.75 [IMAGE AVAILABLE]
- 2. 5,876,718, Mar. 2, 1999, Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies; Randolph J. Noelle, et al., 424/154.1, 130.1, 133.1, 134.1, 141.1, 143.1, 193.1; 435/326, 332, 334, 343, 343.1; 530/388.2, 388.22, 388.7, 388.73, 388.75 [IMAGE AVAILABLE]
- 3. 5,869,049, Feb. 9, 1999, Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists; Randolph J. Noelle, et al., 424/154.1, 130.1, 134.1, 143.1, 144.1, 173.1, 233.1; 514/2, 8, 12 [IMAGE AVAILABLE]
- 4. 5,858,358, Jan. 12, 1999, Methods for selectively stimulating proliferation of T cells; Carl H. June, et al., 424/130.1, 143.1, 154.1; 435/383; 530/387.1, 388.22, 388.7, 388.75 [IMAGE AVAILABLE]
- 5. 5,811,097, Sep. 22, 1998, Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling; James Patrick Allison, et al., 424/144.1, 130.1, 133.1, 135.1, 141.1, 143.1, 152.1, 154.1, 810; 514/2, 12, 885; 530/387.1, 387.3, 388.1, 388.22, 388.7 [IMAGE AVAILABLE]
- 6. 5,747,037, May 5, 1998, Anti-GP39 antibodies; Randolph J. Noelle, et al., 424/154.1, 130.1, 141.1, 143.1, 144.1, 153.1, 173.1; 435/70.21, 326, 332, 334, 343, 343.1, 343.2, 346; 530/387.1, 388.1, 388.2, 388.22, 388.7, 388.73, 388.75 [IMAGE AVAILABLE]
- 7. 5,683,693, Nov. 4, 1997, Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40; Randolph J. Noelle, et al., 424/144.1, 130.1, 133.1, 134.1, 141.1, 143.1, 154.1, 173.1; 514/2, 8, 885 [IMAGE AVAILABLE]

=> d 1-18 115

- 1. 5,885,796, Mar. 23, 1999, CTLA4 receptor and uses thereof; Peter S. Linsley, et al., 435/69.1, 320.1, 325; 530/350; 536/23.1, 23.4, 23.5 [IMAGE AVAILABLE]
 - 2. 5,882,877, Mar. 16, 1999, Adenoviral vectors for gene therapy containing deletions in the adenoviral genome; Richard J. Gregory, et al., 435/320.1, 456, 457 [IMAGE AVAILABLE]
 - 3. 5,877,021, Mar. 2, 1999, B7-1 targeted ribozymes; Dan T. Stinchcomb, et al., 435/366, 6, 91.31, **320.1**, 325; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
 - 4. 5,872,154, Feb. 16, 1999, Method of reducing an immune response to a recombinant adenovirus; James M. Wilson, et al., 424/85.2, 85.5, 93.2,

- 93.6, 154.1, 233.1; 435/69.1, **320.1**; 514/44, 49, 50 [IMAGE AVAILABLE]
- 5. 5,869,230, Feb. 9, 999, Gene transfer into the kid; Vikas P. Sukhatme, 435/1.1; 424/93.2; 435/320.1, 456; 514/44; 536723.1 [IMAGE AVAILABLE]
- 6. 5,858,776, Jan. 12, 1999, Tumor cells with increased immunogenicity and uses therefor; Suzanne Ostrand-Rosenberg, et al., 435/325; 424/93.21; 435/69.1, 320.1, 354, 366, 375 [IMAGE AVAILABLE]
- 7. 5,851,806, Dec. 22, 1998, Complementary adenoviral systems and cell lines; Imre Kovesdi, et al., 435/91.41, **320.1**, 325, 366; 536/24.2 [IMAGE AVAILABLE]
- 8. 5,851,795, Dec. 22, 1998, Soluble **CTLA4** molecules and uses thereof; Peter S. Linsley, et al., 435/69.1, 69.7, 252.3, **320.1**, 325; 530/350, 367, 387.3; 536/23.1, 23.4 [IMAGE AVAILABLE]
- 9. 5,830,698, Nov. 3, 1998, Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same; Mitchell E. Reff, et al., 435/69.1, 320.1, 463, 465; 536/23.2 [IMAGE AVAILABLE]
- 10. 5,820,868, Oct. 13, 1998, Recombinant protein production in bovine adenovirus expression vector system; Suresh K. Mittal, et al., 424/199.1, 233.1; 435/235.1, 320.1 [IMAGE AVAILABLE]
- 11. 5,807,734, Sep. 15, 1998, Monoclonal antibodies and FV specific for CD2 antigen; Michael L. Diegel, et al., 435/252.33; 424/134.1, 135.1, 192.1; 435/70.21, 320.1; 514/44; 530/387.3, 388.22; 536/23.53 [IMAGE AVAILABLE]
- 12. 5,773,253, Jun. 30, 1998, MYPPPY variants of CTL A4 and uses thereof; Peter S. Linsley, et al., 435/69.7, 69.1, 252.3, **320.1**, 358, 361, 362; 530/350, 387.1, 387.3, 388.75; 536/23.5 [IMAGE AVAILABLE]
- 13. 5,741,899, Apr. 21, 1998, Chimeric receptors comprising janus kinase for regulating cellular pro liferation; Daniel J. Capon, et al., 536/23.4; 435/69.7, 320.1, 325, 377; 530/350, 387.3 [IMAGE AVAILABLE]
- 14. 5,670,488, Sep. 23, 1997, Adenovirus vector for gene therapy; Richard J. Gregory, et al., 514/44; 424/93.2; 435/320.1 [IMAGE AVAILABLE]
- 15. 5,652,224, Jul. 29, 1997, Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism; James M. Wilson, et al., 514/44; 424/93.21; 435/320.1, 325, 354, 366, 369, 370, 456 [IMAGE AVAILABLE]
- 16. 5,639,661, Jun. 17, 1997, Genes and proteins for treating cystic fibrosis; Michael J. Welsh, et al., 435/252.3, 320.1; 536/23.5, 24.3 [IMAGE AVAILABLE]
- 17. 5,637,481, Jun. 10, 1997, Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell; Jeffrey A. Ledbetter, et al., fusion proteins in a mammalian cell; Jeffrey A. Ledbetter, et al., 435/69.6, 69.1, 69.7, 320.1, 325, 326, 328, 332, 365 [IMAGE AVAILABLE]
- 18. 5,202,422, Apr. 13, 1993, Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use; Andrew C. Hiatt, et al., 424/132.1, 133.1, 150.1, 804; 435/69.6, 70.21, 188.5, 252.3, 320.1; 530/387.1, 387.3, 388.1, 388.4, 861; 800/288 [IMAGE AVAILABLE]

